Cytosorbents (CTSO) to Release Earnings on Thursday

Cytosorbents (NASDAQ:CTSO - Get Free Report) will be announcing its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The medical research company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. Cytosorbents had a negative net margin of 68.70% and a negative return on equity of 131.84%. The firm had revenue of $9.89 million for the quarter, compared to analyst estimates of $9.73 million. During the same quarter in the previous year, the business posted ($0.14) EPS. On average, analysts expect Cytosorbents to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytosorbents Stock Performance

Shares of NASDAQ CTSO remained flat at $1.01 during midday trading on Thursday. The stock had a trading volume of 53,512 shares, compared to its average volume of 121,783. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.12 and a quick ratio of 1.71. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $2.15. The stock's 50-day moving average price is $1.15 and its two-hundred day moving average price is $1.00. The company has a market capitalization of $54.85 million, a PE ratio of -1.71 and a beta of 0.51.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. StockNews.com started coverage on Cytosorbents in a report on Friday, October 25th. They set a "hold" rating on the stock. HC Wainwright reiterated a "neutral" rating and set a $1.00 price objective on shares of Cytosorbents in a research note on Wednesday, August 14th. Finally, EF Hutton Acquisition Co. I raised shares of Cytosorbents to a "strong-buy" rating in a research report on Monday, July 29th.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.